NASDAQ: AKTXAkari Therapeutics PLC Stock
$0.75+0.02 (+2.74%)
Updated Oct 31, 2025
AKTX Price
$0.75
Fair Value Price
N/A
Market Cap
$48.92M
52 Week Low
$0.57
52 Week High
$2.91
P/E
N/A
P/B
1.91x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.99
Operating Cash Flow
-$9M
Beta
0.41
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKTX Overview
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTX's potential to beat the market
- AKTX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKTX
RankedUnranked of 488
RankedUnranked of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.65 | A | |
| $93.48 | A | |
| $14.66 | A |
Be the first to know about important AKTX news, forecast changes, insider trades & much more!
AKTX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTX is good value based on its book value relative to its share price (1.91x), compared to the US Biotechnology industry average (5x)
P/B vs Industry Valuation
AKTX's cash burn is expected to be positive in the next year ($1.62M), after accounting for decreasing cash burn (82.09%)
Interest Coverage Financials
AKTX's short-term liabilities ($17.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more AKTX due diligence checks available for Premium users.
Valuation
AKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.91x
Industry
5x
AKTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
AKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$50.9M
Liabilities
$25.3M
Debt to equity
0.99
AKTX's short-term liabilities ($17.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's long-term liabilities ($8.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$0.0
Financing
$3.4M
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKTX vs Biotech Stocks
Akari Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.